

TERMINATION LETTER

Date: July 31, 2023

From:

Stellapharm J.V. Co., Ltd. - Branch 1
No. 40 Tu Do Avenue, Vietnam – Singapore Industrial Park
An Phu Ward, Thuan An City, Binh Duong Province,
Vietnam

To:

Medicines Patent Pool
Rue de Varembé 7,
1202 Geneva, Switzerland

RE: Termination of MPP-Stellapharm Nirmatrelvir Sublicense Agreement

Dear Mr. Chan Park,

This letter is written to notify you that we decide to terminate the Nirmatrelvir Sublicense Agreement (this "Agreement") involved by Stellapharm and MPP which was made as of 21 February, 2022.

After carefully evaluating the Nirmatrelvir project, we have observed that the spending and usage of this antiviral medicine have decreased considerably as of now and the outlook for upcoming years in the context of the post-pandemic era. In consideration of the present situation, therefore, we are writing this letter to terminate the Agreement. The termination shall become effective at the end of August 31, 2023, following 30 days from the Agreement's date.

As per the terms and conditions of the Agreement, we shall continue to comply with the obligations set forth in the Agreement and cooperate with MPP until the termination of this Agreement.

We would like to express gratitude for the prompt and dedicated support with reference to Nirmatrelvir project you have been giving us for these past several months.

We are looking forward to future cooperation in other projects in the coming time with MPP.

We are thanking you.

Yours sincerely,

Stellapharm J.V. Co., Ltd. - Branch 1

Nguyen Ngoc Lieu, Pharm.

Deputy General Director



Contact

T +84 274 3767 470
F +84 274 3767 469
E info@stellapharm.com

Office

40 Tu Do Avenue, Vietnam – Singapore
Industrial Park, An Phu Ward, Thuan An
City, Binh Duong, Vietnam

www.stellapharm.com

